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Glycosphingolipid antigens and cancer therapy 
Sen-itiroh Hakomori and Yongmin Zhang 
Specific types of glycosphingolipid (GSL), which are 
chemically detectable in normal cells, are more highly 
expressed in tumors. The high level of expression on the 
surfaces of tumor cells causes an antibody response to these 
GSLs, which can therefore be described as tumor-associated 
antigens. Some of these GSLs have been shown to be 
adhesion molecules involved in tumor cell metastasis, and to 
be modulators of signal transduction controlling tumor cell 
growth and motility. Tumor-associated GSL antigens have 
been used in the development of antitumor vaccines. GSLs 
and sphingolipids involved in adhesion and signaling are 
therefore targets for cancer therapy. 
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Introduction 
The fact that dramatic changes in glycosphingolipid (GSL) 
composition and metabolism are associated with oncogenic 
transformation was first shown three decades ago in studies 
of the in W&J transformation of fibroblasts by tumor viruses 
[1,2]. GSL changes are caused by precursor accumulation 
resulring from blocked synthesis of complex GSLs or 
enhanced synthesis of a certain GSL. In either case, 
changes in glycosyltransferase geocs are involved. GSLs 
are cell-surface antigens, and it was therefore suggested 
that changes in their composition would rt-sulc in changes 
in the antigenicity (ability to bind antibody) and immuno- 
g&city (ability to induce immune response) of the tumor 
cells expressing them (Fig. 1). The idea of GSLs as tumor- 
associated antigens is the basis for attempts to utilize GSLs 
for anticancer vaccine development. 
The first clear support for this idea came when rabbit 
polyclonal antibodies were used to show that the GSL 
Gg3Cer (gangliotriaosylceralnide - GalNAcp4Galp4Gle- 
Cer) is expressed at high levels only in KiMSV sarcoma 
cells grown in BALB/c mice, and not in normal cells or 
tissues [3]. Later, the monoclonal antibody (InAh) approach 
was introduced in tumor immunology, and many studies 
focused on identifying the chemical nature of the previ- 
ously ill-defined ‘tumor-associated antigens’ that had been 
identified using polyclonal antibodies. In one set of experi- 
ments, mAbs were produced by immunizing mice with 
human tumors, cloning antibody-producing hybrigoma 
cells, then selecting antibodies that reacted with the tumor 
cells (but not with normal cells or tissues). These mAbs 
were claimed to react specitically with the twoor cells. SW 
prisingly, however, many such mAbs were directed to 
GSLs, which arc expressed in normal cells as well, although 
the quantity and degree of expression are much lower in 
normal cells. Typical examples of these antigenic CSLs are 
shown in Tables 1 and 2. Many of these antigens have 
since been chemically synthesized [4-131. 
In a second set of more critical experiments, rats or mice 
were immunized with tumors derived frdm genetically 
identical (syngeneic) animals. Animals are usually tolerant 
to their own cells, and cannot raise antibodies to antigens 
they are tolerant to. Therefore, the antibodies that arc 
raised using this experimental protocol should react only 
with antigens that arc unique to the tumor. Nevertheless, 
several such antibodies did react with GSLs in the tumor 
despite the fact that these are present ubiquitously 
in normal tissues. For example GM3 was ideotified as the 
melanoma-associated antigen in mice, hamsters and humans 
[14], Gb3 (globotriaosylceramide, Gal-a4Galp4GlcCerf and 
IV%GalnLc&kr (Gala3Gal~4GlcNAc~3Gal~4GlcCer) 
Conformational structure of globoside, a 
typical C+SL antigen. Note that the axes of 
Complementary Lectins Antibodies 
blytins) / 
the two hydrophobic tails (ceramide, 
GSLs \ consisting of sphingosine and fatty acid) are 
oriented perpendicular to the carbohydrate 
chain. Ceramide holds GSL in the membrane 
such that carbohydrate chain is presented to 
ligands (lectins, selectins, antibodies, 
Ceramide moiety 
Holds GSL carbohydrates in 
defined orientation through 
in*ertion in plasma 
membrane 
Forms GSL microdomains 
(GSL patches) 
GSL entire molecule or derivatives 
Receptor-associated 
complementary GSLs). GSLs themselves, 
ceramide and sphingosine derivatives can all 
affect transmembrane signaling throljgh 
activation or inhibition of various kinases 
involved in the signaling system. 
Cer-activated kinase 
Sphingosine 
Sph-activated kinase 
i 
Signal 
transduction 
were identified as antigens in tibrosarcoma KMT-17 cells 
grown in syngcneic WKA rats [1.5], and extended LcX, 
which includes Le”-Le”, was similarly identified in F9 
teratocarcinoma in mice (Tabies 1,2) [It]. 
These results suggcsr chat although GSLs are present in 
both tumors and normal tissue, they act as efficient 
immunogcns only when they arc prcsent at the surface of 
tumor cells. In the examples above, GM3, Gb3 and LeX 
were chemically detectable in normal tissue, but were not 
immunogenic and not detectable by an antibody binding 
assay. There ate two possible explanations for the uncx- 
pccted ability of the rats and mice to mount antibody 
responses against GSLs. The GSLs found on tumors may 
be antigenically different, in other words they may react 
with different antibodies from the GSLs found on normal 
cells. Alternatively, they may be immunogenically differ- 
ent; this would imply that they arc able to elicit an 
immune response that normal GSLs cannot, and to which 
the animal is therefore not tolerant. 
The difference in the antigenic behavior of tumor GSLs 
may be explained by the arrangement of GSLa in the 
membrane. Electron micrographic studies indicated that 
GSLs are not homogeneously distributed at the wter 
leaflet of plasma membrane, but that they cluster to form 
‘GSL patches’ or detergent-insoluble ‘GSL microdomains’ 
(Fig. 2). The n&b M2590, which reacts specifically with 
mouse, hamster and human melanoma but not with normal 
melanocyres or other normal cells 01 tissues, recognizes 
GM3 in the membrane only when it is above a threshold 
density level [14]. Many other tumor-associated GSL 
antigens, are at high density in tumors and may be orga- 
nized in microdomains at the tumor cell surface. This leads 
to the important idea that it is the density of rumor-associ- 
ated CSLs in tumor cell membranes, above a certain 
‘threshold’ level, that leads to their immunogenicity and 
antigenicity. Above the threshold value, GSl,s cluster to 
form microdomains at the outer leaflet of tumor cell plasma 
membrane and either mAbs or the immune system can EC- 
ognize GSL clusrers in which GSL density is above the 
threshold value. The presence of such microdomains is of 
fundamental importance for the function of GSLs not only 
as antigens, but also as adhesion molccoles and as modula- 
tors or initiators of membrane signaling processes (Fig. 2). 
The ability of GSI,s at the cell surface IO react with anti- 
bodies (antigenicity) and/or to elicit a response from the 
host immune system (immunogenicity) depends not only 
on the presence of GSL microdomains, but also on the 
presence of certain other glycoconjugatcs and ccl1 surface 
molecules (Fig. 2) [17]. 
Why do tumors change GSL composition and 
organization? 
Essentially all experimental and human cancers show strik- 
ing differences in GSL composition and metabolism 
compared to parental normal cells. They also show changes 
in N-linked and O-linked glycosylation in &ycoprotcins, 
particularly in glycoproteins that are involved in cell 
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Disialosyl- 
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animal camera 
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Human 
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Small cell 
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[41 
[51 
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synthesized 
161 
VI 
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Dl 
Glycolipids are abbreviated according to the recommendations of the IUPAC-IiT9 Commission on Biochemical Nomenclature I461. 
adhesion and motility. Abnormal glycosylation in GSLs clinicopathological studies have shown that abnormal glyco- 
and glycoproteins is an essential criterion for’ defining sylation in a primary furnor is strongly correlated with 5 year 
stage, direction and fate of tumor progression. Numerous 01 10 year survival rates of pa+nts [1X]. 
Table 2 
Review Glycosphingolipids and cancer therapy Hakomari and Zhang 101 
Figure 2 
Structure and organization of glycosphingolipid 
antigens at the cell surface. (a) GSLs inserted 
in the plasma membrane tend to form ‘GSL 
microdomains’ when their concentration is 
above a celtain threshold value. GSL ‘patches’ 
are observed under electron microscapy with 
freeze-fracture technique. Glycoproteins (Gp) 
are arranged in clusters that are separate from 
GSL micradomains. Recent studies indicate a 
dynamic interaction between Gp clusters and 
GSL microdomains. and that transducer (TD) 
molecules such as Sm. Ras, Cak and Rho are 
sometimes associated with GSL microdomains. 
The interaction af ligands with GSLs may 
proceed through the microdomains and affect 
the function of the transducer molecules. 
(b) Proposed cell adhesion (phase I) initiated 
through interaction between GSL 
microdomains, followed by (phase II) adhesion 
between adhesive receptors (AR) or involve- 
ment of iectin (L). Phase I is a quick reaction 
(complete within a few minutes) that requires 
only GSL-GSL interaction. Phase II is a slow 
process involving protein-protein interaction. In 
phase 11, transmembrane signaling may occur 
through the cunnecticm of AR to a cytoplasmic 
component, or through the cOnnection of TD 
molecules to the GSL microdomain. 
, 
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Why is this change in glycosylation so important for the 
growth of the tumor? It seems clear that aberrant glycosyla- 
:im in cell~surface receptors modukxcs their function, 
controls motility and adhesion, and promotes tumor-cell 
invasion and progression (see references cited in [1X]). The 
accumulation of large amounts of specific types of aber- 
rantly glycosylated GSLs in specific tumors may thus 
enhance tumor-cell invasion and metastasis through any or 
all of four possible mechanisms. First, the GSL itself may 
be an adhesion molecule which interacts with &tins or 
selectins (carbohydrate-binding receptors) expressed on the 
target cell. Second, the GSJ, may be recognized by another 
GSL expressed on the metastatic target cell. Third, the 
GSL may act indirectly, by modulating an adhesion or 
motility receptor to promote fumor cell invasiveness. 
Fourth, the GSL and/or its degradation products - includ- 
ing lyso-GSLs, de-N-acetyl compounds, sphingosine and its 
derivatives and ceramide - may directly trigger transmem- 
brane signaling that enhances tumor-cell motility and inva- 
siveness. Our knowledge of these possible mechanisms is 
highly fragmentary, however. Only a few cases have been 
studied, as described below. 
GSLs as adhesion molecules and mediators of 
metastasis 
Some GSL antigens that arc highly expressed in specific 
types of human cancer have been identified recently as 
adhesion molecules that may promote tumor-cell mcrasta- 
sis. A few examples ace described below. 
GM3 in mou*e melanoma 616 
The Icvcl of GM3 expression is closely correlated with the 
invasive and metastatic properties of four mouse mela- 
noma Bl6 variants. Blb/BL6 has the highest GM3 expres- 
sion of these furnor lines, and is also rhc mosf invasive and 
metastaric, followed in descending order by FlO, Fl and 
WA4 (which is non-mctastatic and shows minimal GM3 
expression) [19]. Recent studies indicate that GM3 can 
act as an adhesion molecule for IWO other GSLs, Gg3Cer 
and Lac,Cer (lactosylceramide (Gal~/lGlcCer), which are 
expressed in non-activated vascular endothelial cells. The 
metastasis of Bl6 is thus triggered by the recognition of 
rhc GM3 expressed on the melanoma by the Gg3 or 
LacCcr on endothelial cells [19]. This hypothesis is sup- 
ported by the fact that 816 metastasis is blocked by lipo- 
somes containing GM3 or Gg3, or by mAbs raised against 
GM3 or Gg3 [XI]. 
Disialosyl-salactosylslobosida in renal cell carcinoma 
The GSL disialosyl-galactosylgloboside was recently found 
KI be highly expressed in human renal cell carcinoma [Zl]. 
The strucfure is closely related to ‘stage-specific embry- 
onic antigen-4’ and. m GDlu ganglioside (see Table 1). 
Expression of disialosyl-galactosylgloboside is correlated 
with the potential of renal cell carcinoma fo metastasize IO 
the lung. Cell lines derived from renal cell carcinoma 
express high levels of disialosyl-galactosylgloboside and 
adhere strongly fo perialveolar lung tissue sections. This 
adhesion is inhibited by a mAb (RMZ) specifically directed 
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IO disialosyt-galactosylgloboside, but not to monosialosyl- 
galactosylgtoboside. A specific (but as yet unidentitied) 
recepror may be present in lung tissue that recognizes 
renal cell carcinoma [ZZ]. Specific interaction between 
such a receptor and disialosyl-galacrosytgloboside may 
mediate the metastasis of renal cell carcinoma fo the lung. 
Sk+, Sk* and their analogs as ligands for selectins 
The carbohydrate structures SLeX and SLeLLeX [23], and 
SLea [24] were originally identified as human tumor-associ- 
ated antigens. Later, they were found to bind fo the 
endothetiat cell-surface receptors E-selectin and P-selectin 
under certain conditions [ZS-281. Binding to the endorhe- 
lium is a necessary step in the process of metastasis, and so 
this observation explained the fact that tumor cells tend to 
show increased levels of members of the SLeX family. 
Many subsequent extensive studies (e.g. [29,30]) clarified 
that SLex, SLe” and their analogs are indeed involved in 
tumor progression in three ways. First, furnor cells that 
express SLeX, SLea and their analogs, bind to E-setectin in 
activated endothelial cells [2S-7.91. These tumor epitopes 
can be lipid-linked in GSLs or N-linked or O-linked in 
gtycoproteins. Second, leukemic leukocytes show clear 
binding fo P-setectin through a ‘scaffold’ protein, P-selectin 
gtycoprotein ligand 1 (PSGL-1). Scaffold proteins carrying 
SLex family carbohydrates are important for P-seleccin 
binding of leukemic leukocytes, but not important for P- 
selecrin binding of solid fumors (gastric, breast, colon and 
lung) [3O]. Similarly, many common human cancers of 
epitheliat origin do not ‘bind fo P-setcctio unless the 
PSGL-1 gene is also present, even though they may show 
high levels of expression of SLeX or SLea [3O]. Some furnor 
cells show weak PSGL-1-independent P-selectin binding, 
however. Third, many tumor cells activate platelets to 
release an as yet unidcntificd factor that triggers E-selcctin 
expression in endotheliat cells [18]. 
Any of these three mechanisms or some combination of 
them would be expected fo promote metastasis, primarily 
by allowing furnor cells fo bind fo microvascular endothe- 
lial cells. Patients with primary tumors expressing SLe”, 
SLea or their analogs survived for a significantly shorter 
time than patients whose fumo~s did nor express these 
epitopes (see [1X] for review). 
E-selectin and P-selectin were originally identified as 
adhesion receprors at the surface of activated endothelial 
cells and platelets. They are involved in rolling/tethering 
neutmphils, monocyres, and certain lymphocyte sub- 
populations. This process is regarded as the initial step in 
the inflammatory response, the body’s basic defence 
mechanism, The real physiological epitope present in ncu- 
trophils and other hematopoietic cells was recently charac- 
terized as being not simple SLeX or SLe”, but rather 
as long-chain, unbranchcd poty-N-acetyl-tactosamines 
(collectively termed ‘myeloglycan’) having a sialosyl 2-13 
substitution ar the terminal Gal, and multiple fucosylarion 
at an internal (but not the penultimate) GlcNAc 1311. 
Rolling/tethering of ~-selectin-expressing cells to myeto- 
glycan is more prominent under dynamic flow conditions 
than rolling/tethering of the same cells to SLeX 1321. Thus, 
it is important to distinguish SLex and SLe” from myelo- 
gtycan-type epitopes. SLex and SLc” have a primary func- 
tion in cancer metestasis and invasion, whereas 
myetoglycan-type epitopcs are involved in the inflamma- 
tory response under dynamic flow conditions. 
GSLs as modulators of tumor cell signaling 
GSLs, particularly gangliosides and their degradation 
products, are also believed to conuol cell growth, by mod- 
ulating key molecules involved in signal transduction 1331. 
Current research trends arc focused on the functional roles 
of ceramide and sphingosine, and their derivatives, as 
second messengers in signal transduction [34,35]. 
Our current knowledge of the relationship between GSL 
composition, metabolism, and their effect on signal frans- 
duction in tumor cells is highly fragmentary. GM3 in 
melanoma binds to LacCer or Gg3Cer through GSL-GSL 
interactions. The process of interaction, which increases 
the motility of melanoma cells, must trigger certain 
signals; it may induce signal transduction [36]. GM3 and 
other gangtiosides that accumulate in mmors may activate 
specific types of integrin involved io transmembrane sig- 
naling, such as oi3p1. a$;, and a$1 (see [l&3] for review). 
GSLs and cancer therapy 
Immunotherapy and vaccine development 
Antibodies that are directed fo GMZ, GD2 and other GSLs 
are detectable in the semm of patients with melanoma. It 
is not clear whether the antibody production is triggered by 
the patient’s immune response to the tumor, or by environ- 
mental factors (e.g. intestinal flora). Many studies indicate 
that antibiotics present in sera of normal subjects and 
cancer patients are directed fo environmental factors, 
which directly stimulate an immune response through 
‘Peyer’s patches’ on intestinal mucosal epirhelia. The anti- 
body level in some (but not all) patients with certain types 
of cancer is higher than in normal subjects. Therefore the 
autotogous immune response fo the tumor’s own GSLs is 
still under debate. It has been suggested that increasing 
the level of antibodies artificially by active immunization 
with GM2 or GD2 may suppress melanoma growth. Liv- 
ingston, Lloyd and coworkers have made extensive studies 
in this area [37,38]. They were able to show a large increase 
in antibody titres when the patients were immunized with 
gangliosides covatently linked fo hemocyanin from the 
keyhole limpet, used as a carrier protein. The double bond 
of the sphingosine moiety of GSL was oxidized fo an alde- 
hyde group, which was covatently coupled to the carrier 
protein. Immunization of patients with such &L-protein 
conjugates significantly enhanced both the IgM and IgG 
Review Glycosphingolipids and cancer therapy Hakomori and Zhang 103 
response to GM2 and GD3. T,argc-scale clinical trials with 
melanoma patients arc now under way [3X]. 
Another thcrapcutic approach using antibodies directed to 
GSLs has recently been developed, (e.g. 1391). In this 
approach, a gent: encoding anti-GD2 antibody is fused to B 
gene encoding interleukin-2 (K-Z), and used to produce 
a protein having both anti-GD2 antibody function and 
IL-2 function. IL-2 activates the CDS+ ‘r cell (or ‘killer’ 
cell) response, and the CLX+ cells arc thcrcfore directed 
towards the tumor expressing GD2. A large subcutaneous 
tumor of cells expressing GD2 (derived from B16 
melanoma cells by transfection with the genes for 
pl+4GalNAc transfcrasc and a2-18 sialyltransferase) was 
completely climinatcd by infusion of the anti-GD2-IL-2 
fusion protein. 
Anti-adhesion therapy 
Assuming that curnor cell metastasis and invasion arc initi- 
ated by adhesion of rumor cells to the basement mcm- 
branc, cndothclial cells, platelets and parcnchymatous cells 
in certain organs, blocking of such adhesion may abrogate 
metastasis and invasion. Inrcgrin function is blocked by 
the peptidcs RGDS (a sequc?cc common to various adhe- 
sive proteins) and YIGRS (a scqucncc in laminin), because 
they arc both rccognizcd by integrin rcccptors. Tumor 
metastasis, presumably caused by enhanced integrin func- 
tion, was inhibited by preincubation of tumor cells with 
these peptidcs. 
Another anti-adhesion Qproach is based on GM3. The 
dcgrcc of melanoma cell metastasis depends on the level 
of GM3, and on GM3-dcpendcnt adhesion to Gg3Cer and 
LacCcr in microvascular cndothelial cells (as described 
above). Lung metastasis of Bl6 melanoma can be inhibited 
not only by preincubation of tumor cells with GM3 or Gg3 
liposomcs, but also by intravenous administration of these 
liposomes after primary tumor cells arc established [ZO]. 
Many tumor-associated GSLs arc assumed f” be adhesion 
molecules and to promote metastasis and invasion. Block- 
ing total GSL synthesis may, therefore, suppress these 
processes. A series of studies by Radin and Inokuchi 
[40] demonstrated that o-three-PDMP, an inhibitor of 
P-glucosylation of Cer, depletes most GSLs and inhibits 
tumor growth and metastasis. 
Ortho-signaling therapy 
If tumor cell invasiveness and metastasis depend on signal- 
ing leading to expression of E-selectin “I P-selcctin in 
endothclial cells or platelets, and on signaling created by 
integrin receptors, blocking of these signaling processes 
should inhibit invasion and mcrastasis. P-selectin exprcs- 
sion in micravascular cndothelial cells is highly sensitive f” 
NJ-dimethyl-sphingosinc and N,N,N-trimethyl-sphingo- 
sine; l-3 pM concentrations of these compounds produce 
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